apg -2449
apg -2449: developed by 2 companies · 1 clinical trial tracked. Updated within the last hour.
Lead developer: ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
Development Pipeline (2)
Clinical Trials (1)
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APG-2449 Monotherapy or in Combination With Anticancer Agents in Patients With Platinum-resistant Recurrent Ovarian Cancer or Advanced Solid Tumors
Frequently asked questions
Who is developing apg -2449?
apg -2449 is being developed by ASCENTAGE PHARMA GROUP INTERNATIONAL, CHINA PHARMA HOLDINGS, INC..
How many clinical trials involve apg -2449?
BioSniper tracks 1 clinical trial involving apg -2449.
Analyze ASCENTAGE PHARMA GROUP INTERNATIONAL & apg -2449 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company